The first surgery using the Orbit subretinal delivery system to deliver GT005 to a patient with geographic atrophy secondary to dry age-related macular degeneration has been conducted in the ongoing phase 1/2 FOCUS trial.
Jeffrey Heier, MD, conducted the surgery using Gyroscope Therapeutics’ proprietary Orbit subretinal delivery system (Orbit SDS) to deliver GT005, an investigational gene therapy, without the need for a vitrectomy or retinotomy.
“The Orbit SDS is a very elegant way to deliver the gene therapy without actually having to go inside the eye, into the vitreous cavity and
Uncategorized